← Back to Search

Antibiotic

vancomycin for Clostridium Difficile Infection (StoP CDI Trial)

Phase 4
Waitlist Available
Led By Matthew Sims, MD PhD
Research Sponsored by William Beaumont Hospitals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks after treatment
Awards & highlights

StoP CDI Trial Summary

This trial will test whether giving vancomycin to patients who are already colonized with C. diff will prevent them from getting CDI when they are admitted to the hospital for another infection.

Eligible Conditions
  • Clostridium Difficile (C. diff) Infection

StoP CDI Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks after antibiotics
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks after antibiotics for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The incidence of CDI in inpatients receiving vancomycin prophylaxis vs. placebo who are on high-risk antibiotics and are colonized with toxigenic C. difficile.
Secondary outcome measures
Antibiotics
The outcome of CDI in patients receiving vancomycin prophylaxis vs. placebo.
The prevalence of toxigenic C. difficile colonization among the inpatient population treated with high-risk antibiotics based on C. difficile PCR.
+1 more

StoP CDI Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: vancomycinActive Control1 Intervention
Vancomycin 125 mg by mouth every 6 hours
Group II: PlaceboPlacebo Group1 Intervention
Placebo every 6 hours. A placebo will look like the drug being studied, but have no active ingredients, in this case it will be fruit punch with vitamins added to mimic the taste of vancomycin.

Find a Location

Who is running the clinical trial?

William Beaumont HospitalsLead Sponsor
149 Previous Clinical Trials
111,741 Total Patients Enrolled
Matthew Sims, MD PhDPrincipal InvestigatorBeaumont Health
2 Previous Clinical Trials
141 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many persons are enrolled in this clinical experiment?

"Affirmative. Clinicaltrials.gov indicates that, since its initial posting on December 1st 2016 and most recent update on February 15th 2022, this clinical trial is actively searching for 2500 volunteers across a single location."

Answered by AI

What prior research has been undertaken with regards to the use of vancomycin?

"Currently, 55 different studies are being conducted to investigate vancomycin. Within those experiments, 6 of them have progressed to the third phase of clinical trials. Of these 315 locations where research is taking place, a great deal are located in Jupiter, Florida."

Answered by AI

Has the Food and Drug Administration granted its approval to vancomycin?

"There is a wealth of evidence in support of vancomycin's safety, thus it was given the maximum score of 3."

Answered by AI

Are any additional participants being accepted for this experiment?

"The most current information on clinicaltrials.gov verifies that the trial is actively enrolling participants and has been since it was initially posted in December 2016 and later updated February 2022."

Answered by AI

To what ailments is vancomycin commonly prescribed?

"Vancomycin is an effective therapeutic measure for treating afflictions like staphylococcal infections, infection caused by staphylococci, and enterocolitis brought on by Staphylococcus aureus."

Answered by AI
~157 spots leftby Mar 2025